Lactosaminated Mesoporous Silica Nanoparticles for Asialoglycoprotein Receptor Targeted Anticancer Drug Delivery

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2015 Feb 4

PMID 25643602

Citations 26

Authors

Guilan Quan

Xin Pan

Zhouhua Wang

Qiaoli Wu

Ge Li

Linghui Dian

Bao Chen

Chuanbin Wu

Affiliations

Soon will be listed here.

Abstract

Background: Mesoporous silica nanoparticles (MSNs) have several attractive properties as a drug delivery system, such as ordered porous structure, large surface area, controllable particle size as well as interior and exterior dual-functional surfaces. The purpose of this study was to develop novel lactosaminated mesoporous silica nanoparticles (Lac-MSNs) for asialoglycoprotein receptor (ASGPR) targeted anticancer drug delivery.

Results: Lac-MSNs with an average diameter of approximately 100 nm were prepared by conjugation of lactose with 3-aminopropyl triethoxysilane modified MSNs. Characterization of Lac-MSNs indicated a huge Brunauer-Emmett-Teller (BET) surface area (1012 m(2)/g), highly ordered 2D hexagonal symmetry, an unique mesoporous structure with average pore size of 3.7 nm. The confocal microscopy and flow cytometric analysis illustrated Lac-MSNs were effectively endocytosed by ASGPR-positive hepatoma cell lines, HepG2 and SMMC7721. In contrast, non-selective endocytosis of Lac-MSNs was found in ASGPR-negative NIH 3T3 cells. The cellular uptake study showed the internalization process was energy-consuming and predominated by clathrin-mediated pathway. Model drug docetaxel (DTX) was loaded in the mesopores of Lac-MSNs by wetness impregnation method. In vitro cytotoxicity assay showed that DTX transported by Lac-MSNs effectively inhibited the growth of HepG2 and SMMC7721 cells in a time- and concentration- dependent manner.

Conclusions: These results demonstrated that Lac-MSNs could be a promising inorganic carrier system for targeted intracellular anti-cancer drug delivery.

Citing Articles

Modulating metal-organic frameworks by surface engineering of stearic acid modification for follicular drug delivery and enhanced hair growth promotion.

He Z, Liu Z, Zhang Y, Guo T, Feng N J Nanobiotechnology. 2025; 23(1):118.

PMID: 39966985 PMC: 11834556. DOI: 10.1186/s12951-025-03234-z.

Glycan-Silica Nanoparticles as Effective Inhibitors for Blocking Virus Infection.

Perez-Alonso C, Lasala F, Rodriguez-Perez L, Delgado R, Rojo J, Ramos-Soriano J ACS Appl Mater Interfaces. 2025; 17(7):10292-10304.

PMID: 39908032 PMC: 11881045. DOI: 10.1021/acsami.4c15918.

Delivery of Avocado Seed Extract Using Novel Charge-Switchable Mesoporous Silica Nanoparticles with Galactose Surface Modified to Target Sorafenib-Resistant Hepatocellular Carcinoma.

Basu A, Sae-Be A, Namporn T, Suriyaphan O, Sithisarn P, Leanpolchareanchai J Int J Nanomedicine. 2024; 19:10341-10365.

PMID: 39430309 PMC: 11488512. DOI: 10.2147/IJN.S478574.

Investigating layer-by-layer chitosan-dextran sulfate-coated mesoporous silica as a pH-sensitive drug delivery system.

Hooshyar M, Raygan S, Aghdam R J Mater Sci Mater Med. 2024; 35(1):29.

PMID: 38884680 PMC: 11182833. DOI: 10.1007/s10856-024-06797-9.

Structural elucidation and development of azelaic acid loaded mesoporous silica nanoparticles infused gel: Revolutionizing nanodrug delivery for cosmetics and pharmaceuticals.

Arshad T, Shoaib Khan H, Akhtar N, Hanan H, Hussain M, Kazi M Heliyon. 2024; 10(8):e29460.

PMID: 38665554 PMC: 11043944. DOI: 10.1016/j.heliyon.2024.e29460.

References

Barreto J, OMalley W, Kubeil M, Graham B, Stephan H, Spiccia L . Nanomaterials: applications in cancer imaging and therapy. Adv Mater. 2011; 23(12):H18-40. DOI: 10.1002/adma.201100140. View

Tsai C, Vivero-Escoto J, Slowing I, Fang I, Trewyn B, Lin V . Surfactant-assisted controlled release of hydrophobic drugs using anionic surfactant templated mesoporous silica nanoparticles. Biomaterials. 2011; 32(26):6234-44. DOI: 10.1016/j.biomaterials.2011.04.077. View

Benezra M, Penate-Medina O, Zanzonico P, Schaer D, Ow H, Burns A . Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011; 121(7):2768-80. PMC: 3223837. DOI: 10.1172/JCI45600. View

Morelli C, Maris P, Sisci D, Perrotta E, Brunelli E, Perrotta I . PEG-templated mesoporous silica nanoparticles exclusively target cancer cells. Nanoscale. 2011; 3(8):3198-207. DOI: 10.1039/c1nr10253b. View

He Q, Gao Y, Zhang L, Zhang Z, Gao F, Ji X . A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials. 2011; 32(30):7711-20. DOI: 10.1016/j.biomaterials.2011.06.066. View

Shi D, Bedford N, Cho H . Engineered multifunctional nanocarriers for cancer diagnosis and therapeutics. Small. 2011; 7(18):2549-67. DOI: 10.1002/smll.201100436. View

Yang H, Lou C, Xu M, Wu C, Miyoshi H, Liu Y . Investigation of folate-conjugated fluorescent silica nanoparticles for targeting delivery to folate receptor-positive tumors and their internalization mechanism. Int J Nanomedicine. 2011; 6:2023-32. PMC: 3181061. DOI: 10.2147/IJN.S24792. View

Lu J, Li Z, Zink J, Tamanoi F . In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine. 2011; 8(2):212-20. PMC: 3221805. DOI: 10.1016/j.nano.2011.06.002. View

Muthu M, Kulkarni S, Raju A, Feng S . Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials. 2012; 33(12):3494-501. DOI: 10.1016/j.biomaterials.2012.01.036. View

10.

Khosroushahi A, Naderi-Manesh H, Yeganeh H, Barar J, Omidi Y . Novel water-soluble polyurethane nanomicelles for cancer chemotherapy: physicochemical characterization and cellular activities. J Nanobiotechnology. 2012; 10:2. PMC: 3286383. DOI: 10.1186/1477-3155-10-2. View

11.

Liu Q, Zhang J, Xia W, Gu H . Magnetic field enhanced cell uptake efficiency of magnetic silica mesoporous nanoparticles. Nanoscale. 2012; 4(11):3415-21. DOI: 10.1039/c2nr30352c. View

12.

Fang I, Slowing I, Wu K, Lin V, Trewyn B . Ligand conformation dictates membrane and endosomal trafficking of arginine-glycine-aspartate (RGD)-functionalized mesoporous silica nanoparticles. Chemistry. 2012; 18(25):7787-92. DOI: 10.1002/chem.201200023. View

13.

Wang X, Li X, Ito A, Sogo Y, Ohno T . Particle-size-dependent toxicity and immunogenic activity of mesoporous silica-based adjuvants for tumor immunotherapy. Acta Biomater. 2013; 9(7):7480-9. DOI: 10.1016/j.actbio.2013.03.031. View

14.

Mamaeva V, Sahlgren C, Linden M . Mesoporous silica nanoparticles in medicine--recent advances. Adv Drug Deliv Rev. 2012; 65(5):689-702. DOI: 10.1016/j.addr.2012.07.018. View

15.

Kwon S, Singh R, Kim T, Patel K, Kim J, Chrzanowski W . Luminescent mesoporous nanoreservoirs for the effective loading and intracellular delivery of therapeutic drugs. Acta Biomater. 2013; 10(3):1431-42. DOI: 10.1016/j.actbio.2013.10.028. View

16.

Zhou J, Pishko M, Lutkenhaus J . Thermoresponsive layer-by-layer assemblies for nanoparticle-based drug delivery. Langmuir. 2014; 30(20):5903-10. DOI: 10.1021/la501047m. View

17.

Zhang Q, Neoh K, Xu L, Lu S, Kang E, Mahendran R . Functionalized mesoporous silica nanoparticles with mucoadhesive and sustained drug release properties for potential bladder cancer therapy. Langmuir. 2014; 30(21):6151-61. DOI: 10.1021/la500746e. View

18.

Ow H, Larson D, Srivastava M, Baird B, Webb W, Wiesner U . Bright and stable core-shell fluorescent silica nanoparticles. Nano Lett. 2005; 5(1):113-7. DOI: 10.1021/nl0482478. View

19.

Tang Q, Xu Y, Wu D, Sun Y, Wang J, Xu J . Studies on a new carrier of trimethylsilyl-modified mesoporous material for controlled drug delivery. J Control Release. 2006; 114(1):41-6. DOI: 10.1016/j.jconrel.2006.05.006. View

20.

Kim K, Lei Y, Stolz D, Liu D . Bifunctional compounds for targeted hepatic gene delivery. Gene Ther. 2007; 14(8):704-8. DOI: 10.1038/sj.gt.3302917. View